BioCentury
ARTICLE | Emerging Company Profile

Novelix: Dogging cancer

June 11, 2007 7:00 AM UTC

With about 300 small molecule cancer candidates, Novelix Pharmaceuticals Inc. believes it has enough shots on goal to be able to carve out a chosen few for itself and use the rest to fund internal development. Even for molecules it chooses to keep, the company will pursue early revenue opportunities by out-licensing non-cancer indications and by doing cancer studies in canine models that will double as clinical trials to support initial veterinary approval and as preclinical studies to support INDs.

"While most startup companies are one-trick ponies, we have an unusually large pipeline, allowing us to generate revenues through early licensing opportunities while advancing our key compounds in key indications within the company," President and CEO Burkhard Jansen told BioCentury...